GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
WEB3 days ago — Oct 9 (Reuters) - GSK (GSK.L) has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2
WEB2 days ago — GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
WEB2 days ago — The Food and Drug Administration asked in 2020 that all Zantac products, which relied on a heartburn drug developed by GSK, be taken off the market. The current Zantac 360 uses a different active ...
Statement: Zantac (ranitidine) litigation – settlement ... - GSK
WEB3 days ago — 09 October 2024. Issued: London, UK. For media and investors only. Statement: Zantac (ranitidine) litigation – settlement agreements reached. Download (PDF, 130.6KB) GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion. Separate settlement of …
GSK reaches $2.2bn heartburn medication Zantac settlement in US
WEB3 days ago — GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
WEB3 days ago — GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was contaminated with ...
Pharmaceuticals giant GSK to pay $2.2bn to settle Zantac lawsuits
WEB2 days ago — UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement …
WEB3 days ago — On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company. Under these agreements, GSK will pay up to $2.2 billion to resolve the claims, contingent upon eligibility and participation ...
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
WEB2 days ago — GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was contaminated with a suspected carcinogen.
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
WEB3 days ago — Photo: Drew Angerer/Getty Images. GSK GSK 3.22% agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...
- Some results have been removed